How can cfONCO- Breast help you?
Oxford offers you cfONCO- Breast, non-invasive test through next generation screening technology, to test the mutation of breast cancer (including the latest SNP highly relate with the breast cancer.) It is also provided with targeted drugs recommendation approved by FDA, assisted treatment alternatives, post-treatment monitoring and evaluation of targeted drugs, early detection of drugs resistance in cancer targeted treatment. 

 
 Highlight: 
  • Non-Invasive- provide an alternative to sbustitue for breast cancer tissue sample and senior patients as well. Only a tube of plasma sample is valid for the test. The volume of cfDNA test is different for each patient, and the least volume is only 1 ng.
  • Low limit of detection- Enable variant detection down to 0.1%, with 90% sensitivity and >98% specificity for SNV hoptspots and indels.
  • High value content-  more than 150 hotspots, including TP53 Mutations associated、ERBB2, Mutations associated with sensitivity to anti- ERBB2 therapies etc.
  • Enable tumor heterogeneity- A breakthrough of heterogeous cancer cells which might cause drugs resisistance. ctDNA test helps to monitor somatic mutation from time to time. 
 
cfONCO- Breast
Content
AKT1, EGFR, ERBB2, ERBB3, ESR1, FBXW7, KRAS, PIK3CA, SF3B1and TP53
> 150 hotspots
SNVs and INDELs  including:
PIK3CA: E545K and H1047R、AKT1: E17K、ESR1: Mutations associated with anti-estrogen resistance、TP53: Mutations associated with loss of function、ERBB2: Mutations associated with sensitivity to anti-、ERBB2 therapies
Technology
Next Generation Sequencing
Participants
Primary Breast cancer
Substitute for breast cancer tissue sample
Senior patients
Significance
ctDNA test helps to monitor somatic mutation from time to time. 
Concept of Analysis
The results of screening will compare with Human Genome version 19 (hg19). The drug database provides FDA-approved cancer target drugs.
* please call or email if you need more information